EquitySector - HealthcareVery High Risk
Regular
NAV (20-Dec-24)
Returns (Since Inception)
Fund Size
₹12 Cr
Expense Ratio
0.21%
ISIN
INF740KA1UF4
Minimum SIP
-
Exit Load
-
Inception Date
01 Feb 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
+27.74%
— (Cat Avg.)
Equity | ₹12.11 Cr | 99.96% |
Others | ₹0 Cr | 0.04% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹2.65 Cr | 21.89% |
Treps / Reverse Repo Investments | Cash - Repurchase Agreement | ₹1.69 Cr | 13.98% |
Net Receivables/Payables | Cash | ₹-1.69 Cr | 13.94% |
Cipla Ltd | Equity | ₹1.16 Cr | 9.60% |
Divi's Laboratories Ltd | Equity | ₹1.08 Cr | 8.89% |
Dr Reddy's Laboratories Ltd | Equity | ₹1.01 Cr | 8.36% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1 Cr | 8.28% |
Apollo Hospitals Enterprise Ltd | Equity | ₹0.95 Cr | 7.84% |
Lupin Ltd | Equity | ₹0.68 Cr | 5.63% |
Aurobindo Pharma Ltd | Equity | ₹0.49 Cr | 4.03% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.42 Cr | 3.47% |
Alkem Laboratories Ltd | Equity | ₹0.41 Cr | 3.35% |
Zydus Lifesciences Ltd | Equity | ₹0.33 Cr | 2.75% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.32 Cr | 2.63% |
Laurus Labs Ltd | Equity | ₹0.31 Cr | 2.54% |
Ipca Laboratories Ltd | Equity | ₹0.29 Cr | 2.39% |
Syngene International Ltd | Equity | ₹0.23 Cr | 1.93% |
Biocon Ltd | Equity | ₹0.23 Cr | 1.87% |
Abbott India Ltd | Equity | ₹0.2 Cr | 1.65% |
Dr. Lal PathLabs Ltd | Equity | ₹0.15 Cr | 1.25% |
Granules India Ltd | Equity | ₹0.12 Cr | 0.96% |
Metropolis Healthcare Ltd | Equity | ₹0.08 Cr | 0.65% |
Large Cap Stocks
62.80%
Mid Cap Stocks
31.76%
Small Cap Stocks
5.41%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹12.11 Cr | 99.96% |
Standard Deviation
This fund
--
Cat. avg.
15.68%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since February 2024
Since February 2024
ISIN INF740KA1UF4 | Expense Ratio 0.21% | Exit Load - | Fund Size ₹12 Cr | Age 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹32.33 Cr | 47.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹854.32 Cr | 39.5% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹854.32 Cr | 37.6% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹42.05 Cr | 43.4% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹217.92 Cr | 47.7% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹217.92 Cr | 44.9% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2742.91 Cr | 43.0% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2742.91 Cr | 40.9% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹840.57 Cr | 40.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.39 Cr | 42.4% |
Total AUM
₹1,88,524 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Your principal amount will be at Very High Risk